The Telmisartan Market, estimated at USD 4.36 Bn in 2025, is expected to exhibit a CAGR of 3.9% and reach USD 5.71 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Market Dynamics:
Global telmisartan market growth is driven by increasing prevalence of hypertension worldwide. As per World Health Organization (WHO), 1.13 billion people suffered from hypertension in 2015. The risk of hypertension increases with age and according to estimates nearly 2/3rd of people over the age of 60 years suffer from hypertension. Growing geriatric population globally can boost demand for anti-hypertensive drugs like telmisartan. New product launches by leading manufacturers and introduction of generics versions can drive the market growth. Major players continuously focus on developing innovative drug delivery systems to gain competitive advantage. For instance, Boehringer Ingelheim introduced Micardis, which is a telmisartan orally disintegrating tablet used for the treatment of hypertension.
Increasing prevalence of hypertension can drive the global telmisartan market growth
Hypertension or high blood pressure is a major public health issue worldwide. According to the World Health Organization, nearly 1.13 billion people suffered from hypertension in 2015. The prevalence of hypertension increases due to risk factors like sedentary lifestyles, obesity, and unhealthy diets. Telmisartan is a commonly prescribed angiotensin II receptor blocker (ARB) medication for treating hypertension. Its efficacy and favorable side effect profile have made it one of the preferred options for managing high blood pressure. Growing hypertension patient pool can boost demand for telmisartan-based drugs.
Patent expiry of major drugs can offer opportunities for generic formulations
Patent expiry of major blockbuster drugs offers a massive opportunity for manufacturers of generic drugs. The patent for one of the top-selling telmisartan brands expired in November 2021 in the U.S. This enabled many generic drugmakers to launch affordable generic versions of telmisartan tablets in the country. The patent expiry of major branded drugs can drive the telmisartan market growth over the forecast period. Low-cost generic drugs can significantly increase access to treatment for hypertension patients.
Availability of alternative treatment options can hamper the market growth
Global telmisartan market growth can be hampered by availability of alternative treatment protocols and drug formulations. Other ARBs like losartan, valsartan and irbesartan are effective competitive options for treating hypertension. Furthermore, lifestyle changes, diet control and exercise are also pursued as alternatives to drug therapy in some cases. The popularity of alternative anti-hypertensive drug classes like calcium channel blockers and ACE inhibitors can also limit the demand growth potential of telmisartan formulations.
Regulatory compliance issues limiting expansion in developing regions
Various regulatory challenges can hamper the telmisartan market growth in developing Asian and Latin American countries. Strict norms regarding drug quality, clinical trials, manufacturing practices and intellectual property compliance can increase the operating costs in these emerging markets. This acts as a deterrent for global as well as local telmisartan manufacturers targeting developing regions. Issues pertaining to supply chain management, distribution networks and medical infrastructure availability can hamper the market growth. Resolving regulatory hurdles and ensuring norm compliance can create new growth avenues for telmisartan sales in developing Asian and Latin American hypertensive populations.
Growth of e-pharmacies opening digital opportunities
Rising internet and smartphone penetration is facilitating the growth of online pharmacy platforms or e-pharmacies globally. Growing acceptance of e-commerce for medical prescriptions and supplies provides new opportunities for marketing and selling telmisartan drugs through digital channels. Online platforms offer lucrative advantages like enhanced access in remote locations, convenience of home delivery, affordable prices and personalized care. Telmisartan manufacturers collaborating with e-pharmacies can boost awareness, availability and accessibility of their products via digital transformation. This emerging opportunity in digital healthcare can play a vital role in boosting demand for telmisartan formulations worldwide.
Global telmisartan market is witnessing healthy growth supported by rising hypertension prevalence and patent expiries opening opportunities for generic counterparts. Meanwhile, availability of alternative treatments and regulatory bottlenecks in developing regions restrain market expansion. However, growth of e-pharmacies provides promising digital opportunities to further drive telmisartan sales over the forecast period.
Link: https://www.coherentmarketinsights.com/market-insight/telmisartan-market-2524
Key Development
- In May 2024, Akums Drugs and Pharmaceuticals, a Contract Manufacturer in India launched Amlodipine, Telmisartan & Metoprolol (ER) film coated tablets, a fixed-dose combination medication for managing essential hypertension with stable coronary artery disease. Approved by the Drugs Controller General of India (DCGI), this innovative formulation integrates the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and beta-adrenergic blockers into a single tablet.
Key Players: Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
Contact Us